Search results

Order by most recent / most popular / relevance

Results: 1-10 of 18,767

CMS integrity standards offer further details on state-based health insurance marketplaces

Bryan Cave LLP
-
USA
-
June 19 2013

On Friday, the Centers for Medicare and Medicaid Services ("CMS") issued a proposed rule addressing various issues relating to exchanges, small

Federal District Court upholds stark regulation ban on physician-owned under arrangement service providers

Mintz Levin Cohn Ferris Glovsky and Popeo PC
-
USA
-
June 19 2013

On May 24 the District Court for the District of Columbia rejected an appeal brought by a group of urologists ("CUI") seeking to overturn regulations

Supreme Court revives FTC reverse payment challenge; says agreements can violate antitrust laws

Williams Mullen
-
USA
-
June 18 2013

The U.S. Supreme Court has issued one of its more anticipated rulings of this term in a decision that aims squarely at the intersection of antitrust

Hospital worker fails to show that termination for HIPAA violation was discriminatory

Jackson Lewis LLP
-
USA
-
June 18 2013

A hospital lawfully terminated an employee for improperly accessing a co-worker's lab results and refusing to admit to doing so, a federal district

FDA issues guidance detailing specific requirements for Quality Agreements for commercial drug manufacturing

Duane Morris LLP
-
USA
-
June 18 2013

On May 28, 2013, the U.S. Food and Drug Administration (FDA) published a draft guidance ("the Guidance") detailing the FDA's current thinking on

A primer on “low-cost” group health plans

Mintz Levin Cohn Ferris Glovsky and Popeo PC
-
USA
-
June 18 2013

A May 10 Wall Street Journal article, "Employers Eye Bare-Bones Health Plans Under New Law", highlighted a compliance strategy to minimize employer

DNA and genetics patents: what impact will the Myriad decision have?

Dentons
-
USA
-
June 18 2013

Continuing a trend of narrowing the scope of patentable subject matter, the US Supreme Court's recentMyriad decision held that naturally occurring

Supreme Court says ‘reverse payment’ generic drug settlements are subject to rule of reason antitrust review

Debevoise & Plimpton LLP
-
USA
-
June 18 2013

On June 17, 2013, the U.S. Supreme Court issued a much anticipated ruling in Federal Trade Commission v. Actavis, Inc. regarding the validity of

Supreme Court rules that “pay for delay” generic drug patent settlements are not shielded from antitrust liability

Baker & Hostetler LLP
-
USA
-
June 18 2013

The Supreme Court has held that the antitrust laws may forbid patent settlements that delay the market entry of generic drugs in return for large

Not a biotech company? What Myriad might mean for you

Haynes and Boone LLP
-
USA
-
June 18 2013

You've seen all the articles about the Supreme Court's decision in Assoc. For Molecular Pathology v. Myriad Genetics Inc. and the end of DNA patents

next >

Search results

CMS integrity standards offer further details on state-based health insurance marketplaces

Federal District Court upholds stark regulation ban on physician-owned under arrangement service providers

Supreme Court revives FTC reverse payment challenge; says agreements can violate antitrust laws

Hospital worker fails to show that termination for HIPAA violation was discriminatory

FDA issues guidance detailing specific requirements for Quality Agreements for commercial drug manufacturing

A primer on “low-cost” group health plans

DNA and genetics patents: what impact will the Myriad decision have?

Supreme Court says ‘reverse payment’ generic drug settlements are subject to rule of reason antitrust review

Supreme Court rules that “pay for delay” generic drug patent settlements are not shielded from antitrust liability

Not a biotech company? What Myriad might mean for you

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea